BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hidradenitis Suppurativa readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Hidradenitis Suppurat
 iva\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06468228-103@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:lutikizumab: Phase 3 readout est. (NCT06468228)
DESCRIPTION:lutikizumab\, phase 3\, Hidradenitis Suppurativa.\nStudy: A Stu
 dy to Assess Disease Activity and Safety of Lutikizumab in Adult and Adole
 scent Participants With Moderate to Severe Hidradenitis Suppurativa\nEstim
 ated primary completion: December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lutikizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06468228
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06921850-92@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261221
DTEND;VALUE=DATE:20261222
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06921850)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Hidradenitis Suppurativa.\nSt
 udy: A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in C
 hildren and Adolescents With Moderate to Severe Hidradenitis Suppurativa\n
 Estimated primary completion: 21 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bimekizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06921850
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06524635-103@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:lutikizumab: Phase 2 readout est. (NCT06524635)
DESCRIPTION:lutikizumab\, phase 2\, Atopic Dermatitis.\nStudy: A Study to A
 ssess Molecular Changes in Adult Participants With Moderate to Severe Hidr
 adenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receivin
 g Subcutaneous Injections of Lutikizumab\nEstimated primary completion: Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lutikizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06524635
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244263-101@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:zasocitinib: Phase 2 readout est. (NCT07244263)
DESCRIPTION:zasocitinib\, phase 2\, Hidradenitis Suppurativa.\nStudy: A Stu
 dy of Zasocitinib in Adults With Hidradenitis Suppurativa\nEstimated prima
 ry completion: 5 February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/zasocitinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07244263
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07170917-9657@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:SAR442970: Phase 2 readout est. (NCT07170917)
DESCRIPTION:SAR442970\, phase 2\, Hidradenitis Suppurativa.\nStudy: Briveki
 mig for the Treatment of Moderate to Severe Hidradenitis Suppurativa\nEsti
 mated primary completion: 9 February 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sar442970#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07170917
URL:https://assetmemo.bio/drug/sar442970#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06799000-1415@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06799000)
DESCRIPTION:remibrutinib\, phase 3\, Hidradenitis Suppurativa.\nStudy: A Ph
 ase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in 
 Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppura
 tiva (RECHARGE 1)\nEstimated primary completion: 17 May 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/remibrutinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06799000
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840392-1415@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270603
DTEND;VALUE=DATE:20270604
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06840392)
DESCRIPTION:remibrutinib\, phase 3\, Hidradenitis Suppurativa.\nStudy: A Ph
 ase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in 
 Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppura
 tiva\nEstimated primary completion: 3 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/remibrutinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06840392
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07727889-12@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Rinvoq (upadacitinib): Phase 2 readout est. (NCT07727889)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 2\, Hidradenitis Suppurativa.\nSt
 udy: A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidr
 adenitis Suppurativa\nEstimated primary completion: 1 July 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07727889
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287644-1310@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:BFB759: Phase 2/3 readout est. (NCT07287644)
DESCRIPTION:BFB759\, phase 2/3\, Hidradenitis Suppurativa.\nStudy: A Study 
 Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa\nEstimate
 d primary completion: 1 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/bfb759#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07287644
URL:https://assetmemo.bio/drug/bfb759#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225569-11339@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270922
DTEND;VALUE=DATE:20270923
SUMMARY:SAR445399: Phase 2 readout est. (NCT07225569)
DESCRIPTION:SAR445399\, phase 2\, Hidradenitis Suppurativa.\nStudy: A Study
  to Investigate Efficacy and Safety With SAR445399 in Adult Participants W
 ith Moderate to Severe Hidradenitis Suppurativa\nEstimated primary complet
 ion: 22 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sar445399#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07225569
URL:https://assetmemo.bio/drug/sar445399#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07766005-5971@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:SPY072: Phase 2 readout est. (NCT07766005)
DESCRIPTION:SPY072\, phase 2\, Hidradenitis Suppurativa.\nStudy: A Study of
  SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SK
 YLIGHT Trial)\nEstimated primary completion: October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/spy072#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07766005
URL:https://assetmemo.bio/drug/spy072#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05139602-103@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:lutikizumab: Phase 2 readout est. (NCT05139602)
DESCRIPTION:lutikizumab\, phase 2\, Hidradenitis Suppurativa.\nStudy: A Stu
 dy to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-
 981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativ
 a Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Na
 ïve to Biologic Therapy\nEstimated primary completion: December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lutikizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05139602
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007637-104@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280613
DTEND;VALUE=DATE:20280614
SUMMARY:sonelokimab: Phase 3 readout est. (NCT07007637)
DESCRIPTION:sonelokimab\, phase 3\, Hidradenitis Suppurativa.\nStudy: A Stu
 dy to Evaluate the Long-term Safety\, Tolerability\, and Efficacy of Subcu
 taneous Sonelokimab in Participants With Moderate to Severe Hidradenitis S
 uppurativa\nEstimated primary completion: 13 June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sonelokimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07007637
URL:https://assetmemo.bio/drug/sonelokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812116-1@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280616
DTEND;VALUE=DATE:20280617
SUMMARY:duvakitug: Phase 2 readout est. (NCT07812116)
DESCRIPTION:duvakitug\, phase 2\, Hidradenitis Suppurativa.\nStudy: A Study
  to Investigate Efficacy and Safety of Duvakitug in Adult Participants Wit
 h Moderate to Severe Hidradenitis Suppurativa\nEstimated primary completio
 n: 16 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/duva
 kitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07812116
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05889182-12@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT05889182)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Hidradenitis Suppurativa.\nSt
 udy: A Study to Assess Change in Disease Activity and Adverse Events of Or
 al Upadacitinib in Adult and Adolescent Participants With Moderate to Seve
 re Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy\nEstimated pr
 imary completion: August 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/upadacitinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05889182
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783542-1909@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:ORKA-002: Phase 2 readout est. (NCT07783542)
DESCRIPTION:ORKA-002\, phase 2\, Hidradenitis Suppurativa.\nStudy: ORKA-002
  Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppu
 rativa\nEstimated primary completion: October 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/orka-002#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07783542
URL:https://assetmemo.bio/drug/orka-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830329-144@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281124
DTEND;VALUE=DATE:20281125
SUMMARY:olatorepatide: Phase 2 readout est. (NCT07830329)
DESCRIPTION:olatorepatide\, phase 2\, Obesity.\nStudy: Efficacy and Safety 
 of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidraden
 itis Suppurativa Living With Overweight or Obesity\nEstimated primary comp
 letion: 24 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/olatorepatide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07830329
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665437-1415@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20311015
DTEND;VALUE=DATE:20311016
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07665437)
DESCRIPTION:remibrutinib\, phase 3\, Hidradenitis Suppurativa.\nStudy: An E
 xtension Study to Assess Safety and Efficacy of Remibrutinib in Participan
 ts With Moderate to Severe HS\nEstimated primary completion: 15 October 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/remibrutinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07665437
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
